STUDY OF ANTI-AGGREGATE AND ANTITHROMBOTIC EFFECTS OF 11-AMINO ACID DERIVATIVES OF ERYTHROPOETIN OBTAINED USING BLAST SCREENING
The high contribution of cardiovascular pathology to the overall structure of the causes of mortality and disability in the population of developed countries remains relevant to the need for an in-depth study and improvement of methods of treatment and prevention of cardiovascular diseases. Preclinical studies in vitro and in vivo of recent decades have demonstrated that the endogenous stimulator of erythropoiesis with a mass of 34 kDa erythropoietin (EPO) has a high cytoprotective activity, which is mainly associated with the effect on mitochondrial dysfunction and has been confirmed in experimental models. ischemic and traumatic lesions, including endothelium, myocardium and brain. The emergence of information on the realization of the tissue protective effects of erythropoietin through the activation of a heterocomplex consisting of the EPO receptor and CD131 led researchers to the idea of finding short molecules that mimic the erythropoietin helix B for the implementation of the cyto- and athero-protective activity of recombinant erythropoietin. In the present study, we studied the antiplatelet and antithrombotic effects of 11-amino acid derivatives of erythropoietin, which are potential drug candidates for the treatment and prevention of cardiovascular diseases. The study showed the antiplatelet ability in peptide samples with laboratory codes EP-11-1 and EP-11-3, as evidenced by the lengthening of the platelet aggregation time and the decrease in its degree. Intraperitoneal administration of the starting peptide - HBSP led to a shortening of the thrombus formation time to complete cessation of blood flow to 575 ± 22.2 s, which indicates the prothrombogenic effect of the compound. Intraperitoneal administration of the studied peptides EP-11-1 and EP-11-3 led to a statistically significant (p <0.05) lengthening of the thrombus formation time to complete cessation of blood flow to 1097 ± 40.3 s and 1285 ± 57.5 s, respectively. The results of this study indicate the presence of antithrombotic properties in the studied peptides with codes: EP-11-1 and EP-11-3 and their ability to reduce the aggregation ability of platelets.